GlobeNewswire

Finom Pioneers Cryptocurrency Stock Capital in Switzerland

Dela

Finom / Finom Pioneers Cryptocurrency Stock Capital in Switzerland . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Largest increase in stock capital via cryptocurrency in world history and first in Switzerland's Appenzell-Ausserrhoden canton

TEUFEN, Switzerland, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Financial blockchain company Finom AG today announced it has become the first company in the world to increase its stock capital by such an unprecedented level of Ether (ETH) at 7,760 - the second most popular cryptocurrency. Finom's capital stock now comprises 2.5 million Swiss Francs (CHF). The funding is registered in the Finom profile on the Swiss Commercial Register Zefix. This marks the first time a cryptocurrency has been registered as stock capital of a business in Switzerland's Appenzell-Ausserrhoden canton.

Stock capital refers to money or property contributed by stockholders to found a business, and guarantees the insured minimum required for settling accounts with suppliers. Finom officially booked the Ethereum wallet with 7,760 ETH as a non-material asset of the company. This has resulted in the stock capital growing from 0.1 to 2.5 million CHF. The resulting amount is seven times higher than the stock capital of JSC LukOil and 1.6 times higher than that of X5 Retail Group.

"At Finom, we are interested in bringing blockchain to the masses and legitimizing cryptocurrency as a form of stock capital in an innovative manner," said Denis Suslov, Chief Financial Officer at Finom. "This alternative stock capital is fully in alignment with current  legislation on taxation. An independent auditor registers the value of the assets in the wallet under the company's control in its fiat equivalent according to the current exchange rate. Thus, cryptocurrency contributes to the stock capital."

Finom is a financial blockchain corporation grown out of five companies serving over half a million users: NanopoolTabTraderCryptonitCryptal, and Beetle.io. The project releases both a security token (FIN) and a utility token (NOM). The FIN token is being issued pursuant to Regulation D of the U.S. Securities Act of 1933. Its holders will be able to receive dividends and vote as traditional stockholders do. Finom's token sale closes December 30, 2017 with a goal of attracting $102 million.

The Finom ecosystem is designed to eventually facilitate financial operations including banking integration and payments processing. The company plans to introduce cryptocurrency wallets with linked debit cards next year, and to launch a cryptocurrency bank with a network of terminals by 2020.

About Finom
Finom is a financial blockchain corporation grown out of five cryptocurrency companies: Nanopool, TabTrader, Cryptonit exchange, Cryptal mining center and Beetle.io mobile broker. Nanopool is the world's third largest mining pool of Ethereum. TabTrader provides mobile trading on nearly all major exchanges: Bittrex, Bitfinex, Poloniex, Kraken etc. The companies have a four-year partnership history. Finom makes the world of finance available to everyone by providing a blockchain ecosystem with a single point of entry. The company's FIN token, is a digital equivalent of four shares of Finom's common stock. The NOM token serves as the internal currency within the ecosystem and gives its holders ad and commission discounts, and special privileges in using Finom's expected crypto bank cards. Finom's ecosystem allows anyone to manage digital currencies and assets conveniently and in compliance with regulations. For more information, please visit finom.io

Company Contact: Toma Besedina, pr@finom.io 
Media Contact: Transform Group, finom@transform.pr

Disclaimer:

This press release contains statements which, to the extent that they don't recite historical facts, constitute forward-looking statements. These statements can be identified by the fact that they don't relate strictly to historical or current facts and may include the words "may," "will," "expect," "plan" or other words or expressions of similar meaning. These forward-looking statements are based on the current expectations of Finom about future events. Consequently, actual results may differ materially from those that might be anticipated from forward-looking statements. In light of these and other uncertainties, the reader should not regard the inclusion of a forward-looking statement in this press release as a representation by Finom that its plans and objectives will be achieved, and should not place undue reliance on such forward-looking statements. Finom does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Finom via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum